On April 28, 2016 Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, reported four presentations to be delivered at the upcoming American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting (Press release, Kite Pharma, APR 28, 2016, View Source [SID:1234511531]). The presentations will address KTE-C19, Kite’s lead chimeric antigen receptor (CAR) product candidate, and, separately, a fully-human anti-CD19 CAR product candidate for the treatment of B-cell lymphomas and leukemias. The fully-human anti-CD19 CAR product candidate is currently being studied in an ongoing Phase 1 clinical trial as part of a Cooperative Research and Development Agreement (CRADA) between Kite and the National Cancer Institute (NCI). Under this CRADA, Kite collaborates with James (Jim) N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentations:

The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor

Date: Wednesday, May 4, 2016 4:45-5:00PM Eastern Time
Session: Cancer-Targeted Gene and Cell Therapy (3:30-5:30PM Eastern Time)
Abstract Number: 74
Location: Washington 1-2, Marriott Wardman Park
Presenter: Leah Alabanza, Ph.D., Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD

Production of KTE-C19 (Anti-CD19 CAR T Cells) for ZUMA-1: A Phase 1/2 Multi-Center Study Evaluating Safety and Efficacy in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Date: Thursday, May 5, 2016 4:15-4:30PM Eastern Time
Session: Vector and Cell Engineering/Manufacturing (4:00-5:45PM Eastern Time)
Abstract Number: 287
Location: Washington 1-2, Marriott Wardman Park
Presenter: Marc Better, Ph.D., Kite Pharma, Santa Monica, CA

Updated Phase 1 Results from ZUMA-1: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Date: Saturday, May 7, 2016 10:15-10:30AM Eastern Time
Session: Cancer-Immunotherapy, Cancer Vaccines III (10:15AM-12:15PM Eastern Time)
Abstract Number: 745
Location: Thurgood Marshall North, Marriott Wardman Park
Presenter: Frederick Locke, M.D., Moffitt Cancer Center, Tampa, FL

Poster Presentation:

Development of a Manufacturing Process Using Monte Carlo Simulations to Support KTE-C19 (Anti-CD19 CAR T Cells) Studies in Leukemia

Date: Friday, May 6, 2016 6:00-8:00PM Eastern Time
Session: Cancer-Immunotherapy, Cancer Vaccines III
Abstract Number: 650
Location: Exhibit Hall C & B South, Marriott Wardman Park
Presenter: Kenny Choi, Kite Pharma, Santa Monica, CA